Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMA1-C1/Alhydrogel + CPG 7909 malaria vaccine trial
2007-005389-11Phase 2Completed
- Sponsor
- University of Oxford
- Start
- May 2009
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of AMA1-C1/Alhydrogel + CPG 7909 in Falciparum malaria (PF) (2 arms), sponsored by University of Oxford. Primary endpoints: Safety, Immunogenicity and 3 more. Started May 2009; status: completed.
02
Drugs
AMA1-C1/Alhydrogel + CPG 7909
03
Conditions
Falciparum malaria (PF)
Beyond the preview
Go deeper on 2007-005389-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005389-11.